# Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

> **NCT04291092** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- NSCLC Stage IV
- Brain Metastases
- Immunotherapy

## Interventions

- **DRUG:** Immunotherapy
- **RADIATION:** WBRT
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04291092
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2021-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291092, "Camrelizumab Combined With Local Treatment in NSCLC Patients With BM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04291092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*